Welcome to the poster portal for HEP-DART 2023. All accepted abstracts are listed below for your viewing.
Please click the link to review the pdf abstract of the poster presentation which will open in a pop-up window.
If you have any questions regarding the presented data, please use the contact information provided for each presenting author to contact them.
Low prevalence of HDV testing and worse disease outcomes among HDV patients in NYC – results from the INSIGHT database.
Lauren Alpert, Icahn School of Medicine at Mount Sinai
lauren.alpert@icahn.mssm.edu
HDV RNA and HDAg exhibit long half-lives in HDV-infected hepatocytes
Beatrice Ary, Gilead Sciences
beatrice.ary@gilead.com
Liver concentrations of JNJ-73763989 in patients with chronic hepatitis B (CHB): The INSIGHT Study Panel 3 results
Tarik Asselah, AP-HP Hôpital Beaujon, Clichy, France
tarik.asselah@aphp.fr
Early virological efficacy o1 the monoclonal antibody VIR-3434 and siRNA VIR-2218 1or the treatment o1 chronic Hepatitis D Virus: preliminary results from the Phase 2 SOLSTICE trial
Tarik Asselah, AP-HP Hôpital Beaujon, Clichy, France
ABSTRACT
tarik.asselah@aphp.fr
Efficacy and Safety of Bulevirtide in Combination With Pegylated Inter1eron alfa-2a in Patients With Chronic Hepatitis Delta: Primary Endpoint Results From a Phase 2b Open-Label, Randomized, Multicenter Study MYR204
Tarik Asselah, AP-HP Hôpital Beaujon, Clichy, France
tarik.asselah@aphp.fr
Efficacy and safety of siRNA JNJ-73763989, capsid assembly modulator JNJ-56136379, nucleos(t)ide analog (NA), and pegylated interferon alpha-2a (PegIFN-α2a) 1or treatment o1 chronic hepatitis B (CHB): final study results from the phase 2 PENGUIN study
Michael Biermer, Janssen Pharmaceutica
mbiermer@its.jnj.com
A Rhesus Macaque Model of HIV/HBV Co-infection
Sreya Biswas, Oregon Health and Science University
mbiermer@its.jnj.com
Safety, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of ALG-055009, a thyroid hormone receptor beta agonist, in hyperlipidemic subjects and relative bioavailability/food effect of a solid formulation in healthy volunteers
Lawrence Blatt, Aligos Therapeutics, Inc.
lblatt@aligos.com
Novel Diagnostic Assay Testing using Remnant Clinical Samples for Creation and Characterization of SARS-CoV-2 Variant Testing Panels
Heather Bowers, Emory University
hbbower@emory.edu
Transgenic rhesus macaques expressing human sodium taurocholate co-transporting polypeptide are susceptible to hepatitis B infection
Ben Burwitz, Oregon Health & Science University
burwitz@ohsu.edu
Innate immune response to different HDV genotypes in primary human hepatocytes
Josolyn Chan, Gilead Sciences
josolyn.chan12@gilead.com
Transient alanine transaminase increase during bepirovirsen treatment coincides with hepatitis B surface antigen decline in participants with chronic hepatitis B virus infection not currently on nucleos(t)ide analog therapy
Jennifer Cremer, GSK
jennifer.x.cremer@gsk.com
Comparative analysis of human, rodent and snake Kolmioviridae replication
Zoé Denis, Centre National de la Recherche Scientifique (CNRS) - France
zoe.denis@igmm.cnrs.fr
In-person interactions impact on HCV, HIV, and Syphilis Rates in At Risk Populations
Pam Ford, SRx Health Solutions
pam.ford@omeganurses.ca
Promoting Health Equity for Women with Hepatitis C by Reducing Disparities in Research
Catherine Frenette, Gilead Sciences
carrie.frenette@gilead.com
Healthcare seeking behavior and selected gynecological conditions in women with and without hepatitis C: An observational study of women in the United States
Catherine Frenette, Gilead Sciences, Inc.
carrie.frenette@gilead.com
EFFIcacy and Safety at 96 Weeks o1 Bulevirtide 2-mg or 10-mg Monotherapy for Chronic Hepatitis Delta: Results From an Interim Analysis of a Phase 3 Randomized Study
Catherine Frenette, Gilead Sciences, Inc.
carrie.frenette@gilead.com
Preclinical efficacy and saFety o1 ARCUS-POL nucleases For chronic hepatitis B: a potentially curative strategy
Emily Harrison, Precision Biosciences
ABSTRACT
emily.harrison@precisionbiosciences.com
A long-term 3D cell culture model for hepatitis B virus studies
Christopher Jones, Emory University
christopher.edward.jones@emory.edu
N6-Methyladenine Modification of Hepatitis Delta Virus Regulates Its Virion Assembly by Recruiting YTHDF1
Geon-Woo Kim, Chungnam National University
gwkim3142@cnu.ac.kr
Promises and pitFalls o1 implementing the FIND-C artiFIcial intelligence/machine learning algorithm to improve screening eFFIciency in a real-world clinical environment
Bruce Kreter, Gilead Sciences
bruce.kreter@gilead.com
mTORC1 activation promotes systematic M1 macrophage polarity in virus and diet-induced liver FIbrosis
David Lawton, University of Ottawa
dalawton@ohri.ca
Intrahepatic changes in viral and immune markers following treatment with JNJ-73763989 (JNJ-3989) and nucleos(t)ide analogs (NAs), in patients with chronic hepatitis B (CHB): INSIGHT Week 40 (W40) interim results
Oliver Lenz, Janssen Pharmaceutica NV
olenz@its.jnj.com
REP 2139 targets the Hepatitis Delta Virus (HDV) ribonucleoprotein (RNP) and exerts a direct antiviral effect on HDV replication
Massimo Levrero, INSERM U1052
massimo.levrero@inserm.fr
Hedgehog signalling and metabolic responses drive CD8 T cell hyperfunction in advanced liver diseases
Jiafeng Li, University of Ottawa
jli641@uottawa.ca
Impact o1 IFNⱭ on hepatocyte proteome in chronically-in1ected primary human hepatocytes
Lefteris Michailidis, Emory University
ABSTRACT
emicha7@emory.edu
Hepatitis B virus genotype H: Epidemiological, molecular, and clinical characteristics
Arturo Panduro, University of Guadalajara
apanduro53@gmail.com
Design of potent HBV capsid assembly modulators (CAMs) using free energy perturbation (FEP)
Dharmeshkumar Patel, Emory University
dharmeshkumar.j.patel@emory.edu
First-in-human application o1 a novel HBsAg-speci@c TCR T cell therapy (SCG101) shows antiviral and anti-tumor effects in patients with HBV-related hepatocellular carcinoma
Ulrike Protzer, SCG Cell Therapy
protzer@tum.de
VIR-2218 and VIR-3434 therapy is eFFIcacious in preclinical models o1 Hepatitis Delta Virus in1ection
Andreas Puschnik, Vir Bio
apuschnik@vir.bio
Hepatitis C virus RNA is 5’ capped with favin adenine dinucleotide
Lizandro Rene Rivera-Rangel, University of Copenhagen - Co-HEP
qkm664@sund.ku.dk
Preclinical eFFIcacy, saFety and immunogenicity o1 CLB-3000: a potential treatment For patients with chronic Hepatitis B
Aileen Rubio, ClearB Therapeutics
arubio@clearbtherapeutics.com
Monkeypox and vaccinia viral inactivation for safe use on molecular, antigen, and drug-discovery assays
Courtney Sabino, Emory University
csabino@emory.edu
A candidate For NASH therapy, TB-840 attenuates ER-stress and Inflammation in RAW 264.7 cells by the regulations o1 RORⱭ and FGF21
Min Kyung Seo, Therasid Bioscience
mkseo@therasidbio.com
Design OF a Small-Molecule BispeciFIc tether (miniBiT) For the Treatment oF Influenza InFections and expansion of the platform to treat chronic hepatitis B
Imrul Shahriar, Purdue University
ishahria@purdue.edu
The RNA interference therapeutic imdusiran retains activity against hbsag in chronic hepatitis B subjects with baseline nucleotide polymorphisms within the HBV target site
Emily Thi, Arbutus Biopharma
ethi@arbutusbio.com
Safety and efficacy o1 REP 2139-Mg against chronic HBV / HDV co-in1ection with advanced liver disease
Andrew Vaillant, Replicor Inc.
availlant@replicor.com
Antigen-Targeting to cd180 for the treatment of chronic HBV infection
Alan Wahl, Abacus Bioscience
ABSTRACT
awahl@abacusbioscience.com
Concurrent Human Immunodeficiency Virus InFection in Patients with Metabolic DysFunction Associated Steatotic Liver Disease is Associated with SigniFIcantly Greater Risks o1 Liver Disease Progression, Cardiovascular Disease, and All-Cause Mortality
Robert Wong, Stanford/VA Palo Alto
rwong123@stanford.edu
HCV reinfection among people who use drugs (PWUD) treated for HCV infection: A long-term view
Shana Yi, Vancouver Infectious Diseases Center
shana.yi@vidc.ca
Bepirovirsen has intrinsic innate immune activity, distinct from that of other anti-sense oligonucleotides, and induces innate immune response in the liver
Shihyun You, GSK
shihyun.k.you@gsk.com
cccDNA clearance and elimination in HBV infected chimeric mice with humanized liver
Yong-Yuan Zhang, HBVtech
yongyuan@hbvtech.com